Post-partum anemia needs a major concern not only to ensure healthy puerperum, better mother baby bonding, build up iron reserves in the puerperal to have a better quality of life and also to ensure minimized incidence of anemia in next pregnancy and to crucially avoid maternal and perinatal mortalities.This co-morbid condition can be effectively treated with the help of intravenous iron therapy. This study aims to compare the efficacy and safety of intravenous ferric carboxymaltose with intravenous iron sucrose in treating anemia during post-partum period.Iron deficiency anemia is the commonest nutritional deficiency in the world. Similarly maternal anemia is a major health concern especially in pregnancy and reproductive age group and developing countries have the highest incidenc. The following can be the causes of iron deficiency anemia in women during pregnancy- hookworm infestation, improper diet, nutritional deficiencies such as folic acid deficiency, vitamin B12 deficiency, vitamin A deficiency, genetic hemoglobinopathies such as sickle cell anemia and thalassemia, helicobacter pylori, malaria etc. Anemia in pregnant women is much more prevalent in developing countries than in developed countries (52% vs 22.5%). The highest disease burden of anemia in pregnancy is amongst South Asia (80%), Asia (60%), and Africa (52%). There is also the difference between the prevalence rates of anemia in the country, Andhra Pradesh having 33% and Rajasthan having 90% of prevalence rate

This interventional prospective study conducted in the Department of Obstetrics and Gynecology at T.M.U Moradabad, India, encompassed a total of 120 postnatal women in the 2 equal predefined study group, pertaining to- Group A who received intravenous iron sucrose and Group B who received intravenous ferric carboxymaltose. The rise in Hemoglobin and serum ferritin levels and with the evaluation of its safety and tolerance were compared primarily at 24 hr postpartum and secondarily at 3 weeks post treatment amongst the two groups. The mean rise in the hemoglobin level with ferric carboxymaltose was 2.35 gm/dl and with that of iron, sucrose was 1.51 gm/dl (pvalue<.01). The mean rise in the serum ferritin levels with ferric carboxymaltose was 53.03 ng/ml and with iron sucrose was 43.91 ng/ml. (p value<.01). Ferric carboxymaltose was observed to be safer with less adverse events in comparison to the Iron sucrose.

With Regards,
Sara Giselle
Associate Managing Editor
Journal of Medical Physics and Applied Scinces